For those of you who have been following Rational Vaccines (RVx)’s progress and the preliminary results of our Phase I trial of the Theravax^HSV-2 vaccine, I attach below a link to an article just published in Southern Illinois University’s Aspects magazine entitled, “Game Changer.”
The link is here: http://www.siumed.edu/pubs/aspects/40-1/coverstory.html
I believe that you will find that this story is more in-depth than most newspaper articles, and may give you a sense for where the science behind the project lies. On other fronts, I am currently in the process of writing up four manuscripts for publication in 2017, so for the science geeks out there, I hope that the hard data emerges soon to justify the claims that:
- Rational Vaccines has an exclusive license on a proprietary herpes diagnostic test that is light years better than the current standard of care;
- Rational Vaccines has an exclusive license on a proprietary technology for easily making stable cell lines that tightly regulate the expression of any gene of interest (i.e., key to making stable ICP0-complementing cell lines that allow the manufacture of our live HSV vaccines); and
- Rational Vaccines has an exclusive license on a proprietary HSV-2 ICP0- mutant virus vaccine that works very well as a therapeutic HSV-2 vaccine, and which most recipients indicates delivers better control of their genital herpes symptoms than valacyclovir or other antiviral drugs.
2017 should be an interesting year as the data I have been collecting for the past six years on all of these fronts finally starts to come to light. In the meantime, the SIU Aspects article may provide a slightly different perspective relative to what has been published about this research in less in-depth interviews and news articles to date.
– Bill H.